Penn State Milton S. Hershey Medical Center and Children's Hospital
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania, United States11 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 2 | 2026-10-06 | NCT07321912 | |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | Ewing sarcoma, Myosarcoma, Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, connective tissue neoplasm, epithelial neoplasm, liposarcoma, myomatous neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, rhabdomyosarcoma, sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT06541262 | |
| PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, diffuse intrinsic pontine glioma, epithelial neoplasm, glioma, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2026-09-23 | NCT04837547 | |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-09-04 | NCT02559778 | |
| Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-09-03 | NCT06540963 | |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, atypical teratoid rhabdoid tumor, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, connective tissue neoplasm, diffuse intrinsic pontine glioma, embryonal tumor with multilayered rosettes, epithelial neoplasm, glioma, mixed neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, rhabdoid tumor, sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-09-03 | NCT06465199 | |
| Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-09-03 | NCT04301843 | |
| Neuroblastoma Maintenance Therapy Trial | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-09-03 | NCT02679144 | |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-08-12 | NCT05489887 | |
| DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, epithelial neoplasm, glioma, medulloblastoma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-08-12 | NCT04696029 | |
| Beat Childhood Cancer Specimen Banking and Data Registry | childhood malignant neoplasm, neoplasm | Recruiting | Not stated | 2026-02-03 | NCT04715178 |